AYTU vs. KPRX, NRBO, EDSA, COCP, ABVC, TLPH, TRAW, NNVC, AVTX, and TNXP
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Kiora Pharmaceuticals (KPRX), NeuroBo Pharmaceuticals (NRBO), Edesa Biotech (EDSA), Cocrystal Pharma (COCP), ABVC BioPharma (ABVC), Talphera (TLPH), Traws Pharma (TRAW), NanoViricides (NNVC), Avalo Therapeutics (AVTX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical preparations" industry.
Kiora Pharmaceuticals (NASDAQ:KPRX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Kiora Pharmaceuticals has higher earnings, but lower revenue than Aytu BioPharma.
Kiora Pharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 1,232.83%. Aytu BioPharma has a consensus target price of $5.00, indicating a potential upside of 71.23%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Aytu BioPharma.
77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 1.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Aytu BioPharma received 243 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 66.67% of users gave Kiora Pharmaceuticals an outperform vote.
Kiora Pharmaceuticals has a net margin of 0.00% compared to Kiora Pharmaceuticals' net margin of -18.27%. Kiora Pharmaceuticals' return on equity of -41.00% beat Aytu BioPharma's return on equity.
In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 1 articles in the media. Aytu BioPharma's average media sentiment score of -1.00 equaled Kiora Pharmaceuticals'average media sentiment score.
Kiora Pharmaceuticals has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.21, meaning that its stock price is 221% less volatile than the S&P 500.
Summary
Aytu BioPharma beats Kiora Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
